Polycystic ovary syndrome risk factors: Difference between revisions
Jump to navigation
Jump to search
Irfan Dotani (talk | contribs) No edit summary |
Aditya Ganti (talk | contribs) |
||
| (7 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Polycystic ovary syndrome}} | {{Polycystic ovary syndrome}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}} {{ADG}} | ||
==Overview== | ==Overview== | ||
Common risk factors in the development of Polycystic ovary syndrome are [[hyperinsulinemia]] secondary to [[insulin resistance]], [[obesity]], family history of [[PCOS]] among first-degree relatives, [[Adrenarche|premature adrenarche]], fetal androgen exposure, and [[low birth weight]]. | |||
==Risk Factors== | ==Risk Factors== | ||
Common risk factors in the development of Polycystic ovary syndrome are: | |||
*[[Hyperinsulinemia]] secondary to [[insulin resistance]]; associated with [[Diabetes mellitus type 2|type 2 diabetes mellitus]]<ref name="pmid28642705">{{cite journal |vauthors=Sortino MA, Salomone S, Carruba MO, Drago F |title=Polycystic Ovary Syndrome: Insights into the Therapeutic Approach with Inositols |journal=Front Pharmacol |volume=8 |issue= |pages=341 |year=2017 |pmid=28642705 |pmc=5463048 |doi=10.3389/fphar.2017.00341 |url=}}</ref><ref name="pmid28882554">{{cite journal |vauthors=Morford JJ, Wu S, Mauvais-Jarvis F |title=The impact of androgen actions in neurons on metabolic health and disease |journal=Mol. Cell. Endocrinol. |volume= |issue= |pages= |year=2017 |pmid=28882554 |doi=10.1016/j.mce.2017.09.001 |url=}}</ref><ref name="pmid28179813">{{cite journal |vauthors=Morford J, Mauvais-Jarvis F |title=Sex differences in the effects of androgens acting in the central nervous system on metabolism |journal=Dialogues Clin Neurosci |volume=18 |issue=4 |pages=415–424 |year=2016 |pmid=28179813 |pmc=5286727 |doi= |url=}}</ref> | |||
*[[Obesity]] | |||
*Family history of PCOS among first-degree relatives | |||
*[[Adrenarche|Premature adrenarche]] | |||
*Fetal [[androgen]] exposure<ref name="pmid28882554">{{cite journal |vauthors=Morford JJ, Wu S, Mauvais-Jarvis F |title=The impact of androgen actions in neurons on metabolic health and disease |journal=Mol. Cell. Endocrinol. |volume= |issue= |pages= |year=2017 |pmid=28882554 |doi=10.1016/j.mce.2017.09.001 |url=}}</ref> | |||
*[[Low birth weight]] | |||
==References== | ==References== | ||
Latest revision as of 15:24, 18 October 2017
|
Polycystic ovary syndrome Microchapters |
|
Differentiating Polycystic ovary syndrome from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Polycystic ovary syndrome risk factors On the Web |
|
American Roentgen Ray Society Images of Polycystic ovary syndrome risk factors |
|
Risk calculators and risk factors for Polycystic ovary syndrome risk factors |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aditya Ganti M.B.B.S. [2]
Overview
Common risk factors in the development of Polycystic ovary syndrome are hyperinsulinemia secondary to insulin resistance, obesity, family history of PCOS among first-degree relatives, premature adrenarche, fetal androgen exposure, and low birth weight.
Risk Factors
Common risk factors in the development of Polycystic ovary syndrome are:
- Hyperinsulinemia secondary to insulin resistance; associated with type 2 diabetes mellitus[1][2][3]
- Obesity
- Family history of PCOS among first-degree relatives
- Premature adrenarche
- Fetal androgen exposure[2]
- Low birth weight
References
- ↑ Sortino MA, Salomone S, Carruba MO, Drago F (2017). "Polycystic Ovary Syndrome: Insights into the Therapeutic Approach with Inositols". Front Pharmacol. 8: 341. doi:10.3389/fphar.2017.00341. PMC 5463048. PMID 28642705.
- ↑ 2.0 2.1 Morford JJ, Wu S, Mauvais-Jarvis F (2017). "The impact of androgen actions in neurons on metabolic health and disease". Mol. Cell. Endocrinol. doi:10.1016/j.mce.2017.09.001. PMID 28882554.
- ↑ Morford J, Mauvais-Jarvis F (2016). "Sex differences in the effects of androgens acting in the central nervous system on metabolism". Dialogues Clin Neurosci. 18 (4): 415–424. PMC 5286727. PMID 28179813.